BioSpace News Archive

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect,” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced the appointment of Chin Lee, MD, MPH, as Chief Medical Officer, effective March 1, 2022.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technologies, today announced that its management will present at the Oppenheimer 32nd Annual Virtual Healthcare Conference on March 15, 2022.

MONTRÉAL and LAVAL, QC, March 1, 2022 /CNW Telbec/ - Pharmaceutical compounds can behave differently in aqueous solution.

Innovative rhPSMA Theranostic technology has the potential to offer both diagnostic imaging and treatment for patients affected by prostate cancer.

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced fourth quarter and full year 2021 financial results.

Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced a study was published on-line as a pre-proof in the peer-reviewed Journal of Vascular Surgery with data collected using QuantaFlo® under real-world conditions.

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-MarketTM technology platform, today announced financial results for its fourth quarter and full year ended December 31, 2021.

Mablink Bioscience appoints its Chief Development Officer to support the regulatory development of its lead candidate MBK-103, an ADC using its proprietary PSARlink™ linker .

PREVAIL evaluates whether obicetrapib, a novel cholesteryl ester transfer protein (CETP) inhibitor, lowers the risk of adverse cardiovascular outcomes (MACE) in individuals with Atherosclerotic Cardiovascular Disease (ASCVD).

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that the Company will present at the Cowen 42nd Annual Health Care Conference and the Barclays Global Healthcare Conference.